Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid Biopsies

Jack A Schalken, PhD, and E. David Crawford, MD, discuss recent advances in non invasive liquid biopsies for prostate cancer, and the impact of SelectMDx. Keywords: liquid biopsies, SelectMDx, prostate cancer Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid Biopsies Summary Jack A. Schalken, PhD, provides an update on urinary-based biomarkers for prostate cancer. He explains the timeline of research and development for these biomarkers. He traces the significant advances from 2002, when researchers first proved that prostate cancer cells shed through the urine, to present day and the development comprehensive risk calculators, especially SelectMDx. The first in class urine...

Read More